Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001180765
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name Phone

E-Mail Address

#### 144: Issuer Information

Name of Issuer Ascendis Pharma A/S

SEC File Number 001-36815

TUBORG BOULEVARD 12

Address of Issuer HELLERUP DENMARK

DK-2900

Phone 45 70 22 22 44

Name of Person for Whose Account the Securities are To Be Sold MIKKELSEN JAN MOLLER

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

Relationship to Issuer PRESIDENT CHIEF EXECUTIVE OFFICER

#### 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
AMERICAN DEPOSITARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	5292	683342.20	57345613	12/10/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

Title of the Date you Nature of Acquisition Name of Is Date Amount Date of Nature of

Class	Acquired	Transaction	Person from Whom Acquired	this a Gift?	Donor Acquired	of Securities Acquired	•	Payment *
AMERICAN DEPOSITARY SHARES	12/10/2024	RESTRICTED/PERFORMANCE STOCK VESTING	ASCENDIS PHARMA A/S			10146	12/10/2024	SERVICES RENDERED

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Nothing to Report

# 144: Remarks and Signature

Remarks UNDER SECURITIES TO BE SOLD DATE ACQUIRED AND DATE OF PAYMENT VARIOUS DATES

Date of Notice 12/10/2024

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature CONFORMED SIGNATURE ON FILE

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)